打造“生物战士” 精准攻击肿瘤

Core Viewpoint - The innovative intracranial injection method for oncolytic virus therapy enhances the treatment of brain tumors, demonstrating safety and efficacy in treating pediatric diffuse intrinsic pontine glioma (DIPG) [1][6]. Group 1: Oncolytic Virus Therapy - Oncolytic virus therapy is emerging as a disruptive new strategy for cancer treatment, with the potential to revolutionize clinical approaches [2]. - This therapy utilizes engineered viruses that selectively infect and destroy tumor cells while activating the immune system, providing a dual mechanism of action [3][4]. - The modified oncolytic virus (Ad-TD-nsIL12) shows improved targeting of tumor cells and reduced toxicity to normal cells through specific genetic alterations [5][6]. Group 2: Clinical Trials and Efficacy - Recent clinical trials have confirmed the safety of the oncolytic virus Ad-TD-nsIL12, with significant preclinical and clinical evidence supporting its effectiveness [6]. - Global statistics indicate over 200 ongoing clinical trials related to oncolytic viruses, with a substantial portion originating from China, highlighting the rapid advancement in this field [7]. - A notable study demonstrated that a new oncolytic virus (VG161) significantly extended the median overall survival of patients with recurrent liver cancer from 9.4 months to 17.3 months [7]. Group 3: Future Directions - The focus for future research includes enhancing collaboration between basic and clinical research to facilitate the transition of oncolytic virus therapies into clinical practice [7]. - The team plans to explore combination therapies involving oncolytic viruses with surgery, chemotherapy, and antibody treatments to address the heterogeneity of malignant tumors [8].